Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Myelo’s acute radiation syndrome therapy gets FDA orphan drug status
Image: FDA grants orphan drug designation to Myelo Therapeutics’ Myelo001 for the treatment of acute radiation syndrome. Photo: courtesy of The U.S. Food and Drug Administration.
Image: FDA grants orphan drug designation to Myelo Therapeutics’ Myelo001 for the treatment of acute radiation syndrome. Photo: courtesy of The U.S. Food and Drug Administration.